Gilead Sciences (NASDAQ: GILD) is down to a forward P/E of just 6 after slightly missing Wall Street's Q3 profit forecast. Regardless of whether Hillary Clinton or Donald Trump heads into the Oval Office, both candidates agree that prescription drug inflation is currently too high. A quick scan of some of the market's largest biotech companies shows that many are trading at single-digit forward P/Es , or below a PEG of 1 (a level considered to be fundamentally cheap).